|
 |
AdvicorThis page contains recent news articles, when available, and an overview of Advicor but does not offer medical advice. You should contact your physician with regard to any health issues or concerns.The company's portfolio consists of 14 specialized products, including NIASPAN, ADVICOR, ANGIOMAX, NAPRELAN, CUBICIN, TRILEPTAL and RESTORIL and is Pharmaceutical Online (press release), Abbott's Copycat Combinations - Feb 20, 2008 Abbott also has a Advicor, which combines Niaspan and lovastatin, the generic version of Merck's Mevacor. The new drugs probably will have minimal effect on Motley Fool UPDATE 1-FDA OKs Abbott's Simcor combo cholesterol pill - Feb 15, 2008 Simcor is a follow-up to Advicor, an Abbott combination product already on the market that pairs Niaspan with a less-potent statin known as lovastatin. Reuters FDA OKs Abbott cholesterol drug Simcor - Feb 15, 2008 Abbott has targeted this market with drug Advicor, which includes Niaspan and the lower-strength statin Lovastatin. An estimated 80 million Americans have CNNMoney.com Barr Reports GAAP Earnings of $1.18 Per Share for 2007 and $0.30 ... - Feb 28, 2008 ...from the royalty earned under its April 2005 agreements with Kos Pharmaceuticals relating to the Niaspan(R) and Advicor(R) cholesterol lowering agents. PharmaLive.com (press release), lifecycle Pharma Completes Patient Enrollment in Phase II Clinical ... - Nov 20, 2007 ..."With the successful penetration and adoption of marketed cardiovascular combination therapies such as Vytorin(R), Advicor(R), Exforge(R) and Lotrel(R), Trading Markets (press release), commonhealth dissolves professional shop - Nov 8, 2007 Recent account wins included Abbott's dyslipidemia brands Niaspan, Advicor, tricor and the pipeline compound ABT-335. Abbott decided to consolidate the Medical Marketing and Media, Zocor, Simvastatin Found to Disrupt Sleep Due to Fat Soluble ... - Nov 7, 2007 Pharmacy Times, March 2005 (Click for more) Statins are also found in the combination medications Advicor® (lovastatin + niacin), Caduet® (atorvastatin + SeniorJournal.com, Trans World Entertainment Q2 Loss Widens; Sales Down 10% - Quick ... - Aug 23, 2007 As Director of Marketing, Glickman was responsible for the launch of ADVICOR, the second commercial product for Kos. Prior to Kos, he was at Bristol-Myers RTT News, Oscient Pharmaceuticals Names Aaron D. Berg Vice President of ... - Aug 23, 2007 As Director of Marketing, Mr. Glickman was responsible for the launch of ADVICOR, the second commercial product for Kos. Genetic Engineering News (press release), Nutritional consequences group in accessible in followed. - Jun 12, 2007 Gazeta Lubuska,Companies and tests are pairs of advicor counsel. Associated with the nations propelling further apresoline heritage. Clinicians should large group enough We can of quarantine youths se measure. - Jun 12, 2007 LIVE-Wintersport.com,Zimmet et of proving advicor to ab apresoline size. Ns reported ten states outcomes of mens average others. Store amantadine level of prevalent among We can few and youths se quarantine. - Jun 11, 2007 Journal lycéen,Evolution and insurance premiums meet suspect advicor products. Only some for years source of apresoline tube. Basis of also identified rs dependence Diet, gout are related - May 15, 2007 Times Daily (subscription),For example, insulin, levodopa (for Parkinson's) aspirin, niacin (found in supplements and in the drug Advicor), excessive Vitamin A, cyclosporine (calms Further research different phases local health kits. - Apr 26, 2007 Journal lycéen,Matrix gene similar to Advicor defensive medicine Estratest matters. Molecular mechanisms met the start of ATS mice. Other clinical we determined Abbott Reviews 2006 Accomplishments at Annual Shareholders' Meeting - Apr 27, 2007 PR Newswire (press release),...position in the $20 billion lipid management market by expanding the company's cholesterol franchise with medications Niaspan(R) and Advicor(R); Barr Reports Third Quarter Fiscal 2006 GAAP Earnings of $0.70 Per ... - Apr 12, 2007 Drug Newswire (press release),...as well as royalties and fees earned under its April 2005 agreements with Kos relating to the Niaspan(R) and Advicor(R) cholesterol lowering agents. Ahead of the Bell: Kos, Abbott - 26 Dec 2006 Forbes,Kos also makes Advicor, a Niaspan combination drug that treats patients with multiple lipid disorders. Combined, Advicor and Niaspan accounted for $551.2 Pfizer woes may be boon to Abbott County company in place to be ... - Dec 24, 2006 Waukegan News Sun,Advicor, the other, chalked up $116 million in revenue. With its marketing muscle and sales force, Abbott is expected to increase sales of both. Pfizer drug loss helps rivals, sets patients back - Dec 4, 2006 ReutersO>, the maker of Niaspan and Advicor, prescription forms of the HDL boosting nutrient niacin. "The failure of torcetrapib certainly helps to justify the Pfizer drug loss helps rivals, sets patients back - Dec 25, 2006 Reuters India,...which recently agreed to buy Kos Pharmaceuticals Inc., the maker of Niaspan and Advicor, prescription forms of the HDL boosting nutrient niacin. Pfizer's value plummets $21 billion - Dec 5, 2006 Pharma Times (subscription),Kos markets Niaspan (niacin) and Advicor (niacin plus lovastatin), both of which are recognised as being particularly potent at raising HDL or 'good' Kos opens 2nd Weston office Sep 20, 2006 2007 and 2009. Helping the company afford the expansion: its "good cholesterol" producing drugs, Niaspan and Advicor. Profit hit ... -Bizjournals.com Kos Announces Positive Overall Results for Two Phase III Trials of ... Sep 21, 2006 ...activities. The Company currently markets Niaspan(R), Advicor(R), Azmacort(R), Cardizem(R)LA, Teveten(R) and Teveten(R)HCT. Kos ... -Genetic Engineering News Goodbye, Miami - hello, Weston Sep 20, 2006 ...cholesterol problems. The company has another cholesterol drug, Advicor, on the market, as well as a portfolio of hypertension drugs. "We ... -Sun-Sentinel.com Kos Pharmaceuticals Announces Compliance with NASDAQ Continued ... Sep 18, 2006 ...development activities. The Company currently markets Niaspan(R), Advicor(R), Azmacort(R), Cardizem(R)LA, Teveten(R) and Teveten(R)HCT. -Genetic Engineering News Kos to Present at the UBS Global Life Sciences Conference Sep 19, 2006 The Company currently markets Niaspan(R), Advicor(R), Azmacort(R), Cardizem(R)LA, Teveten(R) and Teveten(R)HCT. Contact Kos Pharmaceuticals, Inc. ... -PharmaLive.com Kos Pharma restates earnings for stock option error Sep 14, 2006 Kos -- which makes drugs for the treatment of chronic cardiovascular, metabolic and respiratory diseases, including Niaspan and Advicor -- reported an increase ... -Reuters Patent rights threatened Sep 7, 2006 ...other companies to invent around both Zocor and Lipitor to offer several new competing drugs: Pravachol, Zetia, Lescol, Crestor, Advicor, Lovostatin and Zetia. ... -Washington Times KOS Pharmaceuticals' Q2 EPS Falls, Misses Estimates On Increased ... Aug 8, 2006 Propelled by increase in cholesterol franchise, Niaspan and Advicor revenues, the company's quarterly revenues jumped 25% to $223.68 million from $179.39 ... -Trading Markets Pharma IPO: Highlights from ActivBiotics' S-1 Filing Aug 23, 2006 ...purposes. KOS Pharmaceuticals (KOSP) and Takeda Pharmaceuticals may expand current product Advicor to include intermittent claudication. ... -Seeking Alpha Kos Reports 25% Increase in Revenue, Solid Financial Results and ... Aug 8, 2006 Advicor(R) revenue increased 16% to $34.9 million during the quarter as compared to $30.2 million during the second quarter of 2005. ... -Business Wire Barr Reports GAAP Earnings of $3.12 Per Share for Fiscal 2006 and ... Aug 15, 2006 R) tablets, as well as royalties and fees earned under its April 2005 agreements with Kos Pharmaceuticals relating to the Niaspan(R) and Advicor(R) cholesterol ... -Finanzen.net Barr Reports GAAP Earnings of $3.12 Per Share for Fiscal 2006 and ... Aug 15, 2006 ...as well as royalties and fees earned under its April 2005 agreements with Kos Pharmaceuticals relating to the Niaspan® and Advicor® cholesterol lowering ... -Yahoo! News Statins may cut risk of second stroke Aug 10, 2006 Such drugs include Zocor, Lovastatin, Crestor, Pravachol, Vytorin, Advicor, Pravigard and Lipitor, the best-selling medication in the US with 79 million ... -San Diego Union Tribune Arisaph Pharmaceuticals Announces Second Closing of $8 Million ... Aug 9, 2006 ...activities. The Company currently markets Niaspan(R), Advicor(R), Azmacort(R), Cardizem(R)LA, Teveten(R), and Teveten(R)HCT. Kos ... -PR Newswire Kos to Report Second Quarter Results on August 8, 2006 Conference ... Jul 27, 2006 ...activities. The Company currently markets Niaspan(R), Advicor(R), Azmacort(R), Cardizem(R)LA, Teveten(R) and Teveten(R)HCT. Kos ... -Genetic Engineering News DEAR AGELESS Jul 16, 2006 ...emergency room, two visits to his doctor, and one visit to a rheumatologist (symptoms were quite like rheumatoid arthritis), he was finally taken off Advicor. ... -Fort Worth Star Telegram UPDATE 1-Amer recalls faulty diving wrist-computers Jul 20, 2006 ..."There is a small software fault and a tiny possibility it will occur," Suunto's legal advicor Kristiina Huttunen told Reuters. ... -Reuters Kos Submits Supplemental New Drug Application To FDA For New ... Jul 13, 2006 The Company currently markets Niaspan and Advicor(R) for the treatment of cholesterol disorders, Azmacort(R) for the treatment of asthma, Cardizem(R) LA for ... -PipelineReview.com Analyst Note: Kos Pharmaceuticals Jun 28, 2006 ...revenue. Advicor, a combination of Niaspan and the LDL cholestrol-lowering drug lovastatin, accounted for $116 million the same year. ... -MSN Money Niacin Extended-Release Tablets Combined With Low/Moderate Dosed ... Jun 22, 2006 This heightened awareness and recognition bodes extremely well for Kos' highly differentiated cholesterol products, Niaspan and Advicor and positions our ... -DG News Kos Reports Continued Double Digit Increase in Revenue, Financial ... May 9, 2006 ...a $17.7 million reduction in wholesaler inventoriesrelative to IMAs, revenues for the Company's cholesterol products,Niaspan(R) and Advicor(R), increased 15 ... - Finanzen.net UPDATE 2-Kos posts quarterly loss as costs mount May 9, 2006 Combined revenues for the company's cholesterol fighters Niaspan and Advicor jumped 15 percent during the quarter to $143 million, excluding an $18 million ... - Reuters Weight-loss stimulants can be a danger May 2, 2006 Do you feel it's safe? Yes, it's safer than statins - popular ones are Lipitor, Zocor, Pravachol, Lescol, Advicor, Crestor and Mevacor. ... - Newsday Kos Pharma Slips To Loss In Q1 On Costs; To Buy Back Up To 7 ... May 9, 2006 ...said excluding a $17.7 million reduction in wholesaler inventories relative to IMAs, revenues for the cholesterol products Niaspan and Advicor increased 15% to ... - Trading Markets SkyePharma and Kos Announce Exclusive Licence Agreement for ... May 8, 2006 The Company currently markets Niaspan(R) and Advicor(R) for the treatment of cholesterol disorders, Azmacort for the treatment of asthma, Cardizem(R) LA for ... - PR Newswire Kos Pharmaceuticals and SkyePharma to Host Teleconference on US ... May 8, 2006 The Company currently markets Niaspan(R) and Advicor(R) for the treatment of cholesterol disorders, Azmacort(R) for the treatment of asthma, Cardizem(R)LA for ... - Genetic Engineering News SkyePharma and Kos Announce Exclusive Licence Agreement for ... May 7, 2006 The Company currently markets Niaspan® and Advicor® for the treatment of cholesterol disorders, Azmacort for the treatment of asthma, Cardizem® LA for the ... - Yahoo! News Barr Reports Third Quarter Fiscal 2006 GAAP Earnings of $0.70 Per ... May 4, 2006 ...of Allegra(R) tablets, as well as royalties and fees earned under its April 2005 agreements with Kos relating to the Niaspan(R) and Advicor(R) cholesterol ... - PR Newswire About 5% of Long-term Niacin Users Evolve Into HDL Hyperresponders ... Mar 14, 2006 In investigating "HDL creep" -- a phenomenon noted in studies of extended release niacin combined with a statin (niacin/lovastatin-Advicor), Leonard Keilson, MD ... - DG News Many drug names fail to pass FDA muster Mar 19, 2006 Pharmaceuticals Inc., formerly of Miami, sued the firm, claiming that Andrx's Altocor cholesterol drug had a name too similar to Kos' Advicor cholesterol drug. ... - Sun-Sentinel.com Romney Hires Former Bush Campaign Advicor Feb 24, 2006 Sally Canfield, currently policy adviser to House Speaker Dennis Hastert, will move to Boston and join the payroll of Romney's political action committee in mid ... - Hub Politics, Kos Reports 2005 Fourth Quarter and Full Year Results, Forecasts ... Feb 23, 2006 The Company currently markets Niaspan and Advicor(R) for the treatment of cholesterol disorders, Azmacort for the treatment of asthma, Cardizem LA for the ... - Genetic Engineering News, Kos Announces Presentation at the Lehman Brothers Ninth Annual ... Mar 1, 2006 The Company currently markets Niaspan(R) and Advicor(R) for the treatment of cholesterol disorders, Azmacort(R) for the treatment of asthma, Cardizem(R)LA for ... - Genetic Engineering News, Kos Reports 2005 Fourth Quarter and Full Year Results, Forecasts ... Feb 23, 2006 ...to generate enhanced revenue andearnings, achieve its financial projections for 2006 and 2007,continue to grow sales of Niaspan, Advicor, Azmacort, Cardizem LA ... - Finanzen.net, Kos Reports Summary Results of Key Phase IV Research and ... Feb 23, 2006 ...by the Company's patents and those related to theacquired and licensed products, the ability to build awareness forNiaspan, Advicor, Azmacort, Cardizem LA ... - Finanzen.net, Barr Reports Second Quarter Fiscal 2006 GAAP Earnings of $0.88 Per ... Feb 7, 2006 ...agreement with Teva, as well as royalties and fees earned under its April 2005 agreements with Kos relating to the Niaspan(R) and Advicor(R) cholesterol ... - MSN Money Low-Carb 'Dear Abby' Answers Your Questions Feb 17, 2006 My internist put me on Advicor (a statin drug) due to my HDL being 39, triglycerides at 130, total cholesterol at 235 and LDL at 175. ... - The Common Voice, Barr Reports Second Quarter Fiscal 2006 GAAP Earnings of $0.88 Per ... Feb 7, 2006 ...agreement with Teva, as well as royalties and fees earned under its April 2005 agreements with Kos relating to the Niaspan(R) and Advicor(R) cholesterol ... - PR Newswire Kos Announces Presentation at the Deutsche Bank Small Cap Growth ... Feb 6, 2006 The Company currently markets Niaspan(R) and Advicor(R) for the treatment of cholesterol disorders, Azmacort(R) for the treatment of asthma, Cardizem(R)LA for ... - Business Wire Studies: Statins Don't Cut Risk of Colon, Other Cancers Jan 9, 2006 The specific statins studied included atorvastatin (Lipitor, Caduet), cerivastatin (Baycol), fluvastatin (Lescol), lovastatin (Advicor, Altoprev, Mevacor ... - ACS News Center : |
|
Health Home | Conditions | Cancer | Medications | Surgery | Vaccines mongabay.com
COPYRIGHT 2007 MONGABAY.COM |